281 related articles for article (PubMed ID: 32021100)
1. Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis.
Yang H; Li N; Zhou Y; Xiao Z; Tian H; Hu M; Li S
Drug Des Devel Ther; 2020; 14():157-165. PubMed ID: 32021100
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
Laires PA; Ejzykowicz F; Hsu TY; Ambegaonkar B; Davies G
J Med Econ; 2015; 18(8):565-72. PubMed ID: 25788039
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
Davies GM; Vyas A; Baxter CA
J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults.
Xiang Y; Gan L; Du H; Hao Q; Aertgeerts B; Li S; Hu M
Int J Technol Assess Health Care; 2023 Aug; 39(1):e53. PubMed ID: 37650314
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C;
Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925
[TBL] [Abstract][Full Text] [Related]
7. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Rees A; Wilkinson A; Durrington P; Chilcott J
Am J Cardiovasc Drugs; 2008; 8(6):419-27. PubMed ID: 19159125
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.
Ara R; Tumur I; Pandor A; Duenas A; Williams R; Wilkinson A; Paisley S; Chilcott J
Health Technol Assess; 2008 May; 12(21):iii, xi-xiii, 1-212. PubMed ID: 18485273
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial.
Almalki ZS; Guo JJ; Alahmari A; Alotaibi N; Thaibah H
Heart Lung Circ; 2018 Jun; 27(6):656-665. PubMed ID: 28716519
[TBL] [Abstract][Full Text] [Related]
15. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
Nherera L; Calvert NW; Demott K; Humphries SE; Neil HA; Minhas R; Thorogood M
Curr Med Res Opin; 2010 Mar; 26(3):529-36. PubMed ID: 20014994
[TBL] [Abstract][Full Text] [Related]
17. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia.
Strilchuk L; Tocci G; Fogacci F; Cicero AFG
Expert Opin Pharmacother; 2020 Apr; 21(5):531-539. PubMed ID: 32036729
[No Abstract] [Full Text] [Related]
18. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
Reckless J; Davies G; Tunceli K; Hu XH; Brudi P
Value Health; 2010; 13(6):726-34. PubMed ID: 20561328
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
[TBL] [Abstract][Full Text] [Related]
20. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
